Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Christian Thiede, Katja Sockel et al.|Blood|2025Cited by 5
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLChristoph Röllig, Leo Ruhnke, Christoph Schliemann et al.|Annals of Hematology|2025Cited by 4